Skip to main content

Table 3 Individual patient data results for each study and treatment at baseline and 12 weeks

From: Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

 

PLBO

TIO 18

SAL 50

FOR 12

IND 300

IND 150

IND 75

FEV1

SGRQ

FEV1

SGRQ

FEV1

SGRQ

FEV1

SGRQ

FEV1

SGRQ

FEV1

SGRQ

FEV1

SGRQ

B2334, 2008;

N

371

347

    

379

359

389

372

    

B

1.3

43.6

    

1.3

44.3

1.3

44.5

    

sd

0.5

17.8

    

0.4

17.3

0.4

17.1

    

12 wks

1.4

41.6

    

1.4

39.1

1.4

38.5

    

sd

0.5

18.5

    

0.5

18.4

0.5

17.9

    

B2335S, 2008;

N

376

347

393

374

    

389

375

389

368

  

B

1.3

45.7

1.2

44.6

    

1.2

44.6

1.3

45.4

  

sd

0.5

17.3

0.5

18.1

    

0.5

18.7

0.5

19.1

  

12 wks

1.3

42.7

1.4

41.0

    

1.4

39.5

1.5

39.9

  

sd

0.5

18.3

0.5

18.4

    

0.5

18.9

0.5

19.6

  

B2336, 2009

N

316

294

  

316

300

    

320

309

  

B

1.3

43.6

  

1.3

43.2

    

1.3

43.6

  

sd

0.5

17.8

  

0.5

18.5

    

0.5

18.7

  

12 wks

1.3

42.4

  

1.4

37.7

    

1.5

35.9

  

sd

0.5

19.6

  

0.5

18.5

    

0.6

19.4

  

B2346, 2008

N

189

187

        

201

199

  

B

1.3

48.7

        

1.3

50.1

  

sd

0.6

18.9

        

0.6

18.9

  

12 wks

1.4

47.6

        

1.5

43.9

  

sd

0.6

19.2

        

0.6

19.7

  

B23354, 2010

N

148

142

          

149

147

B

1.3

49.5

          

1.3

48.6

sd

0.5

17.3

          

0.5

18.7

12 wks

1.3

47.6

          

1.4

42.8

sd

0.5

17.3

          

0.5

18.2

B23355, 2010

N

150

145

          

145

148

B

1.3

50.1

          

1.4

51.2

sd

0.5

18.1

          

0.5

18.1

12 wks

1.3

49.2

          

1.5

46.2

sd

0.5

20.1

          

0.6

20.0

  1. Mean and standard deviations (sd) presented; IND 75 OD = Indacaterol 75 μg once daily; IND 150 OD = Indacaterol 150 μg once daily; Formoterol 12 μg twice daily; TIO 19 OD = Tiotropium 18 μg once daily; SAL 50 BID = Salmeterol 50 μg twice daily; PLB = Placebo; FEV1 = Forced expiratory volume in 1 second; SGRQ = St. George’s Respiratory Questionnaire; TDI = Transition Dyspnea Index; L = Litres; B = Baseline; 12 wks = 12 weeks; N = sample size of data included at 12 weeks. Note: Minor differences in the outcomes compared to the study publications are present due to missing data in the covariate values for this analysis.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us